- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
European Nurses Boost Biosimilar Education With Newly Translated Guide to Switching
The European Specialist Nurses Organisation has launched 7 new translations of its guide to the management of switches between reference biologics and biosimilars.
The European Specialist Nurses Organisation (ESNO) has launched 7 new translations of its guide to the management of switches between reference biologics and biosimilars. In addition to the original version in English, the guide is now available in German, French, Spanish, Polish, Italian, Portuguese, and Dutch.
The translations of the guide are available to be downloaded at ESNO’s website and are also made available in hard copy by the ESNO office.
Ber Oomen, executive director at ESNO, said in a statement announcing the translations, “Nurses play a very important role in guiding a patient through their treatment path. Our aim with the guide was to empower the nurse in their interactions with their patients. By translating the guide in to 7 additional languages, we aim to educate even more of the nursing community by providing the information in their language.”
The guide, which was originally launched last year, addresses the specific role of the specialized nurse in interacting with patients during the switching process.
The guide is built on existing European Commission guidelines for the healthcare community, and it emphasizes the nurse’s key link between the prescriber and patient and role in treatment adherence.
The included in the guide are definitions of biologic and biosimilar medicines, information about switching and substitution, information on the benefits of using biosimilars, information on the nurse’s role in managing the switch, pharmacovigilance guidance, case studies, real-world evidence, and flow charts that describe how the switch, follow-up, and support processes will unfold for patients.
The ENSO has previously indicated that the guide will eventually be translated into 23 EU languages.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
